Clinical Trials Cultivation Data Environment 
Cannabis Law Report
OCTOBER 6, 2021
Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).
Cannabis Law Report
MAY 29, 2022
A new cultivation facility that is hoping to change lives with psychedelic mushrooms had their grand opening on Friday in Princeton, after being awarded a dealer’s license in February by Health Canada. And there are literally hundreds of trials that are being done, and more forthcoming.”. Optimi Health Corp.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 30, 2019
The consultation covers proposed licensing, cultivation, manufacturing and product standards, and a prescription and enforcement regime. But even if there is no doubt that a regulated market would provide a safer environment for access, we argue that there could be a potential cost to patient safety.
Cannabis Law Report
FEBRUARY 2, 2022
– Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA). Dr. Manalo-Morgan has spent the last 5 years researching cannabis and has specialized in the formulation of cannabinoid products for clinical trials.
Cannabis Law Report
JANUARY 6, 2022
NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, announced today the appointment of accomplished business leader and cannabis industry expert Tim Leslie as the Chairman of its newly formed Advisory Board. Forward-looking statements are only predictions.
Cannabis Law Report
JULY 4, 2019
The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer. About EMMAC.
Cannabis Law Report
JANUARY 18, 2019
iCAN is committed to accelerate Israel’s Canna-Technology industry, capitalizing on Israeli innovation and a leading cannabis regulatory environment to bring premier products to market. Several of these products have already completed or been approved for clinical trials in Israel. About iCAN: Israel-Cannabis.
Expert insights. Personalized for you.
52 
Let's personalize your content